Following guidance from u.s. food & drug administration in type-c meeting lipella pharmaceuticals to advance lead product candidate to phase 2b

Pittsburgh, may 21, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company, announced today the receipt of u.s. food & drug administration (“fda”) type-c meeting guidance regarding the lp-10 (liposomal tacrolimus) clinical program. lipella expects to initiate a phase 2b clinical trial evaluating lp-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024.
LIPO Ratings Summary
LIPO Quant Ranking